news
Lysosomes key to coronavirus shedding, finds study
Scientists reveal that coronaviruses de-activate lysosomes before using them to exit infected cells and spread through the body.
List view / Grid view
Covid-19
news
Leveraging flow cytometry to explore COVID-19 immune responses
Researchers used flow cytometry to characterise which types of T cells are involved in the immune response to COVID-19 and what they target.
news
New imaging method reveals glycan vaccine targets on HIV molecules
Using cryo-electron microscopy and site-specific mass spectrometry, researchers have mapped the glycans that shield HIV from the immune system.
news
Flow cytometry market to exhibit CAGR of 12 percent
A new report has said that by 2023, the flow cytometry market will be worth $8.88 billion, partly due to an increase in stem cell research.
news
Mini lung organoids reveal early SARS-CoV-2 infection process
Using lung organoids, researchers have shown that 48 hours after SARS-CoV-2 infection, the innate immune response began.
article
Treating cytokine storms in COVID-19 patients
Enosi Life Science researchers Sir Marc Feldmann, Dr H Michael Shepard and Dr Fiona McCann explain why anti-TNF therapies may be effective in treating COVID-19 associated cytokine storms and other inflammatory conditions.
![A coiling protein 'shell,' called a nucleocapsid, shown here, surrounds Ebola's genetic material, which consists of single-strand RNA. University of Delaware researchers are simulating the way molecules of this nucleocapsid move and interact, atom by atom, to understand their functions and expose targets for anti-viral treatments [Credit: Juan Perilla Laboratory].](https://drug.russellpublishing.co.uk/wp-content/uploads/Ebola-nucleocapsid-e1603365997854.jpg)
news
The nucleocapsid as a novel drug target for Ebola virus
Using supercomputer stimulations researchers reveal that the structural stability of the Ebola nucleocapsid is depended on the presence of RNA and interactions with charged ions.
news
Severe COVID-19 symptoms may not be caused by cytokine storm
An analysis reveals that in comparison to other inflammatory diseases such as cytokine-release syndrome (CRS) and sepsis, the levels of cytokines in severely ill COVID-19 patients is low.
news
SARS-CoV-2 also uses neuropilin-1 to infect human cells
Researchers reveal that SARS-CoV-2 is more infectious than SARS-CoV because it can use both ACE2 and neuropilin-1 to infect cells.
news
CBD could treat inflammation caused by COVID-19, study shows
Researchers have found that CBD reduces inflammation in the lungs of COVID-19 mouse models by increasing levels of the apelin peptide.
news
First draft sequence of human proteome released
Researchers have mapped 90 percent of the human proteome, which could inform the development of new medicines.
news
SARS-CoV-2 papain-like protease could be a novel drug target
Scientists suggest targeting the SARS-CoV-2 papain-like protease (PLpro) with inhibitors could prevent the spread of infection.
news
Targeting host proteins could lead to pan-coronavirus antivirals
Researchers suggest that targeting host proteins with drugs, rather than directly targeting enzymes or proteins on SARS-CoV-2 and related coronaviruses, could improve outcomes.
news
Study reveals roles of antibodies in SARS-CoV-2 disease severity
Researchers have found that the level of antibodies in the serum of SARS-CoV-2 patients correlated with disease severity.
news
Over 200 molecules and genes linked to COVID-19 severity
A team has identified 219 molecules and genes that influence the severity of COVID-19 in patients, providing information that could aid the development of therapeutics.
